EGRX LOW RISK AND HIGHT REWARD
EGRX broke another key resistance zone, it is in a nice zone to a long entry.
And today:
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announced that the 505(b)(2) New Drug Application (NDA) for its novel ready-to-use bivalirudin product (“RTU bivalirudin”) has been accepted for filing by the U.S. Food and Drug Administration (FDA).
finance.yahoo.com/news/eagle-pharmaceuticals-rtu-bivalirudin-nda-110000493.html
And today:
Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announced that the 505(b)(2) New Drug Application (NDA) for its novel ready-to-use bivalirudin product (“RTU bivalirudin”) has been accepted for filing by the U.S. Food and Drug Administration (FDA).
finance.yahoo.com/news/eagle-pharmaceuticals-rtu-bivalirudin-nda-110000493.html
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。